Endogenous biomarkers for transporter‐mediated drug‐drug interaction (DDI) predictions
represent a promising approach to facilitate and improve conventional DDI investigations in …

Transporters contribute to renal elimination of drugs; therefore drug disposition can be
impacted if transporters are inhibited by comedicant drugs. Regulatory agencies have …

With numerous drugs cleared renally, inhibition of uptake transporters localized on the
basolateral membrane of renal proximal tubule cells, eg, organic anion transporters (OATs) …

Kidney plays a critical role in the elimination of xenobiotics. Drug–drug interactions (DDIs)
via inhibition of renal organic anion (OAT) and organic cation (OCT) transporters have been …

Renal impairment (RI) is a major health concern with a growing prevalence. RI leads to
various physiologic changes, in addition to a decrease in glomerular filtration rate, that …

The greater utilization and acceptance of physiologically‐based pharmacokinetic (PBPK)
modeling to evaluate the potential metabolic drug–drug interactions is evident by the …

The role of membrane transporters on pharmacokinetics (PKs), drug–drug interactions
(DDIs), pharmacodynamics (PDs), and toxicity of drugs has been broadly recognized …

Drug–drug interactions are a major concern not only during clinical practice, but also in drug
development. Due to limitations of in vitro–in vivo predictions of transporter-mediated drug …

Abstract Drug-Drug Interactions Involving Renal OCT2/MATE Transporters: Clinical Risk
Assessment May Require Endogenous Biomarker-Informed Approach Moreover, I in vitro i …

Endogenous biomarkers are discussed as tools for detection of drug‐drug interactions
(DDIs) mediated by renal transport proteins, such as organic cation transporter 2 (OCT2) …